Toronto, Jan 02 — Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada’s #1 cannabis company by market share1, today announced the expansion of its innovation investment in Phylos Bioscience Inc. (“Phylos”), securing Organigram’s position as a leader in seed-based cannabis genetics. Through an amended loan and product agreement, Organigram gains priority access to Phylos’ autoflower genetics pipeline, including preferential economic terms and long-term rights in its international markets, establishing a foundation for product differentiation and growth in recreational and medical markets.
Operational Security Through a Long-Term Seed Pipeline
According to Borna Zlamalik, SVP Innovation & International R&D at Organigram, “Seed-based cultivation has become a key advantage of Organigram’s cultivation strategy, giving us unprecedented consistency, scalability, and economic benefit. Our follow-on investment in Phylos secures the portfolio breadth of next-generation cultivars required to meet the needs of Organigram’s consumers and patients.”
International Exclusivity for Genetics
Under the amended product agreement, Organigram receives five-year exclusivity on its chosen autoflower cultivars across international markets, including Canada, Australia, the UK, Germany, and Israel, with the ability to add new exclusive territories as it expands globally. Annual portfolio reviews will maintain exclusivity only for commercially relevant cultivars, maximising flexibility and strengthening Organigram’s international product differentiation strategy as it enters high-value medical markets.
Convertible Loan Top-Up
Under the terms of the amended loan agreement, Organigram will consolidate its existing investment with a new US$3 million advance, resulting in a combined total loan principal of US$10 million. The loan matures on May 25, 2028, and is subject to conversion or other resolution mechanisms under the amended agreement.
Investing in the Future of Seed-Based Cannabis
Ralph Risch, CEO of Phylos, noted: “Organigram saw early that the next phase of cannabis production would be driven by scientifically bred genetics. Their investment allows Phylos to accelerate development of new traits and F1 hybrid seeds, while giving Organigram a meaningful economic advantage as the first to deploy those innovations at commercial scale.”